Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Low-Carb Diet May Stunt Prostate Tumor Growth

By Drug Discovery Trends Editor | November 13, 2007

A diet low in carbohydrates may help stunt the growth of prostate tumors, according to a new study led by Duke Prostate Center researchers. The study, in mice, suggests that a reduction in insulin production possibly caused by fewer carbohydrates may stall tumor growth.

“This study showed that cutting carbohydrates may slow tumor growth, at least in mice,” said Stephen Freedland, M.D., a urologist at Duke University Medical Center and lead researcher on the study. “If this is ultimately confirmed in human clinical trials, it has huge implications for prostate cancer therapy through something that all of us can control, our diets.”

Freedland conducted most of the research for this study while doing a fellowship in urology at Johns Hopkins’ Brady Urological Institute under the tutelage of William Isaacs, PhD, a molecular geneticist there.

The researchers published their results in the online edition of the journal Prostate. The study was funded by the Department of Veterans Affairs, the Department of Surgery and the Division of Urology at Duke University Medical Center, the Prostate Cancer Foundation, and the Department of Defense Prostate Cancer Research Program.

The researchers hypothesized that since serum insulin and a related substance known as insulin-like growth factor (IGF) had been linked with the growth of prostate tumors in earlier research in mice, a reduction in the body’s levels of these substances might slow tumor growth, Freedland said.

Release date: November 13, 2007

Source: Duke University Medical Center


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50